Ironwood Pharmaceuticals Opens New Manufacturing and Development Facility in Medford, Massachusetts to Support First Human Clinical Trial

CAMBRIDGE, Mass. – November 2, 2010 – InVivo Therapeutics Corporation (“InVivo Therapeutics”), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has signed a lease to open its first manufacturing and development facility in Medford, Massachusetts. The company expects to use this new facility to scale up the manufacturing process for its lead product candidate, a novel biocompatible polymer scaffolding device used to treat acute open-wound SCI. Frank Reynolds, CEO of InVivo Therapeutics, said “This new development laboratory and manufacturing facility represents a critical component of our strategy and brings us one step closer to launching our first human clinical trial. We will put the space to use immediately while working toward securing a larger, commercial-scale cGMP facility here in the Commonwealth of Massachusetts.”

InVivo expects to commence a human clinical trial of its novel biocompatible polymer scaffolding device upon U.S. Food and Drug Administration (FDA) clearance of an investigational device exemption (IDE) application.

About InVivo Therapeutics

InVivo Therapeutics Corporation is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital in Boston.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

Contacts:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com